News
The secondary endpoints of the study were evaluated in adults who achieved a clinical response (EASI 75 or vIGA-AD 0/1 without rescue use at week 24 ... vice president of Research and Development at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback